Multilevel Mechanisms of Cancer Drug Resistance
1Department of Clinical Neuropsychology, Collegium Medicum, Nicolaus Copernicus University, 85-067 Bydgoszcz, Poland.
Abstract:
Cancer drug resistance represents one of the most significant challenges in oncology and manifests through multiple interconnected molecular and cellular mechanisms. Objective: To provide a comprehensive analysis of multilevel processes driving treatment resistance by integrating recent advances in understanding genetic, epigenetic, and microenvironmental factors. This is a systematic review of the recent literature focusing on the mechanisms of cancer drug resistance, including genomic studies, clinical trials, and experimental research. Key findings include the following: (1) Up to 63% of somatic mutations can be heterogeneous within individual tumors, contributing to resistance development; (2) cancer stem cells demonstrate enhanced DNA repair capacity and altered metabolic profiles; (3) the tumor microenvironment, including cancer-associated fibroblasts and immune cell populations, plays a crucial role in promoting resistance; and (4) selective pressure from radiotherapy drives the emergence of radioresistant phenotypes through multiple adaptive mechanisms. Understanding the complex interplay between various resistance mechanisms is essential for developing effective treatment strategies. Future therapeutic approaches should focus on combination strategies that target multiple resistance pathways simultaneously, guided by specific biomarkers.
Insights
Cancer drug resistance arises from complex genetic, epigenetic, and microenvironmental factors. Targeting multiple resistance pathways simultaneously is crucial for effective cancer treatment strategies.
Area of Science:
- Oncology
- Cancer Biology
- Genetics
Background:
- Cancer drug resistance is a major obstacle in oncology, driven by diverse molecular and cellular mechanisms.
- Understanding these mechanisms is critical for improving patient outcomes and developing novel therapeutic strategies.
Purpose of the Study:
- To comprehensively analyze the multilevel processes driving cancer treatment resistance.
- To integrate recent advances in genetic, epigenetic, and microenvironmental factors contributing to resistance.
Main Methods:
- Systematic review of recent literature.
- Inclusion of genomic studies, clinical trials, and experimental research on cancer drug resistance mechanisms.
Main Results:
- Tumor heterogeneity: up to 63% of somatic mutations can be heterogeneous, promoting resistance.
- Cancer stem cells exhibit enhanced DNA repair and altered metabolism, contributing to resistance.
- Tumor microenvironment (fibroblasts, immune cells) and radiotherapy selective pressure significantly promote resistance phenotypes.
Conclusions:
- A complex interplay of genetic, epigenetic, and microenvironmental factors drives cancer drug resistance.
- Future therapies must adopt combination strategies targeting multiple resistance pathways.
- Biomarker-guided approaches are essential for personalized and effective cancer treatment.
More Related Videos
08:46Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
10:24Generation of Heterogeneous Drug Gradients Across Cancer Populations on a Microfluidic Evolution Accelerator for Real-Time Observation
Published on: September 19, 2019
Related Concept Videos
02:56Treatment Resistant Cancers
02:40Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:30Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...